Key clinical point: Niraparib improves PFS when given after first-line chemotherapy for advanced OC.
Major finding: PFS was 21.9 vs. 10.4 months in the treatment vs. placebo groups, respectively (HR, 0.43).
Study details: A phase 3 study of 728 patients.
Disclosures: The PRIMA/ENGOT-OV26/GOG-3012 study was sponsored by TESARO. Dr. González-Martin reported relationships with numerous pharmaceutical companies.
González-Martin A et al. ESMO 2019: Abstract LBA1.